LABCORP ANNOUNCES ADDITIONAL INFORMATION IN CONNECTION WITH ITS SPIN-OFF OF FORTREA

BURLINGTON, N.C., June 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, previously announced the following record and distribution dates for its spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"):

• The record date will be 5:00 p.m. Burlington, North Carolina time on Tuesday, June 20, 2023, and
• The distribution date will be 11:59 p.m. Burlington, North Carolina time on Friday, June 30, 2023.

Fortrea will hold Labcorp's Clinical Development and Commercialization Services business. The spin-off is expected to be effected through the distribution of 100 percent of the common stock of Fortrea to holders of Labcorp's common stock whereby Labcorp's stockholders will receive one share of Fortrea common stock for every share of Labcorp common stock they hold as of the record date.

As previously announced, the U.S. Securities and Exchange Commission ("SEC") declared Fortrea's Registration Statement on Form 10 effective on June 9, 2023, and, also on June 9, 2023, NASDAQ approved the listing of Fortrea's common stock on the NASDAQ Stock Market under the symbol "FTRE." The Registration Statement on Form 10 includes information regarding Fortrea's business and the spin-off of Fortrea from Labcorp.

Labcorp expects that a "when-issued" public trading market for Fortrea's common stock will begin on or around June 16, 2023, under the symbol "FTREV," and will continue through the distribution date. Labcorp also anticipates that "regular-way" trading of Fortrea's common stock will begin on July 3, 2023, the first trading day following the distribution date.

Beginning on or around June 16, 2023, and through the distribution date, it is expected that there will be two ways to trade Labcorp common stock – either with or without the distribution of Fortrea common stock. Labcorp stockholders who sell their shares of Labcorp common stock in the "regular-way" market (that is, the normal trading market on the New York Stock Exchange ("NYSE") under the symbol "LH") during this time period will be selling their right to receive shares of Fortrea common stock in connection with the spin-off. Alternatively, Labcorp stockholders who sell their shares of Labcorp common stock in the "ex-distribution" market during the same period on the NYSE under the symbol "LH WI" will not be selling their right to receive shares of Fortrea common stock in connection with the spin-off. Investors are encouraged to consult with their financial advisors regarding the specific implications of buying or selling shares of Labcorp common stock on or before the distribution date.

The completion of the spin-off remains subject to customary closing conditions.

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 80,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.9 billion in 2022. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

About Fortrea
Fortrea is a leading provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. Fortrea partners with emerging and large biopharma, medical device, and diagnostic companies to drive healthcare innovation and improve the lives of patients worldwide.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the ability to successfully complete the spin-off on a tax-free basis, within the expected time frame or at all, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in (i) with respect to Labcorp, Labcorp's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, including in each case under the heading Risk Factors, and in Labcorp's other filings with the SEC and (ii) with respect to Fortrea, Fortrea's registration statement on Form 10 filed with the SEC on May 15, 2023 (as amended and further supplemented). These forward-looking statements are based on management's current expectations and are subject to certain risks, uncertainty and changes in circumstances including, without limitation, whether the spin-off will be consummated on the expected terms, or at all. Neither Labcorp nor Fortrea undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

SOURCE Labcorp